In contrast, non-tumorigenic HMEC, luminal (MCF7, ZR75-1, T47-D, and BT474), and HER2-eriched (SKBR3) breast cancer cell lines were less sensitive to the combinations, indicating the unique vulnerability of TNBC cells to combinational therapies. Here, ERBB2 is linked to breast cancer.